Navigation Links
Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
Date:7/31/2013

BOSTON, July 31, 2013 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery and development biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a Phase I Small Business Technology Transfer  (STTR) award from the National Cancer Institute of the National Institutes of Health. The Phase 1 award supports the research and development of Arisaph's small molecule immune modulators to stimulate tumor immunity following treatment with BRAF inhibitors in cancer. Following the successful completion of the research, the Company may be eligible for up to $2 million of additional Phase 2 funding to further the development of its immune modulator program for the treatment of melanoma. To date, Arisaph has received in excess of $55 million of non-dilutive capital, including $2.8 million awarded under the U.S. government's Therapeutics Discovery Project Program (TDPP) and $37 million from royalty monetizations leveraging the Company's DPP 4 inhibitor patent estate.

(Logo: http://photos.prnewswire.com/prnh/20110321/NE69091LOGO )

"We are delighted to receive our third small business grant from the NIH in support of our promising oncology programs, which could enhance the efficacy of existing therapies, such as BRAF inhibitors, for the treatment of melanoma," said Christopher P. Kiritsy, President and Chief Executive Officer. "This award continues the string of government grants and other non-dilutive support, enabling the Company to advance its pipeline in an investor friendly manner."

Arisaph has leveraged its medicinal chemistry expertise to develop a class of small molecule immune modulators to boost the immune system to fight various cancers. Such immune modulators are expected to enhance the efficacy of various
'/>"/>

SOURCE Arisaph Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Summary This report ... pharmaceutical companies regarding their Information & Communications Technology ... companies currently allocate their ICT budgets across the ... IT services, communications, and consulting. Key ... companies highlights that X% of respondents anticipate an ...
(Date:9/30/2014)... Investor-Edge has initiated coverage on the following ... Zentaris Inc. (NASDAQ: AEZS ), OPKO Health ... (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). ... at: http://investor-edge.com/register . On Monday, September ... 0.14%, the Dow Jones Industrial Average finished the day ...
(Date:9/30/2014)... 2014  Come fall, many children, teenagers, and even ... want to be for Halloween. And, a number of ... contact lenses bought without a prescription. Halloween, ... purchase and wear contact lenses without a prescription. According ... consumer survey, 17 percent of Americans have worn ...
Breaking Medicine Technology:ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3
... Quantros, a leading software and services provider for ... with Det Norske Veritas Healthcare, Inc. (DNV). DNV ... Medicare and Medicaid Services (CMS) as an authorized ... accreditation standards into the Quantros ACE(TM) software application. ...
... N.Y., Nov. 13 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a new, three year distribution agreement ... distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) ...
Cached Medicine Technology:Quantros Announces Partnership With Hospital Accreditation Agency DNV 2Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE) 2Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE) 3
(Date:9/30/2014)... ADOAMNI, Inc. reached its ... GoFundMe. The campaign, which surpassed its goal in 17 ... the funds necessary to convert a diesel powered bus ... School District (SUSD). The campaign rallied citizens of the ... the funds necessary for the conversion of a SUSD ...
(Date:9/30/2014)... 2014 More than 23 per cent of Canadians report ... stress increases the risk of poor mental and physical health, ... but for others especially those most likely to sweat ... , Thankfully, new research from Concordia University has found a ... huge help for healthcare professionals working to stop stress before ...
(Date:9/30/2014)... the University of Pittsburgh School of Dental Medicine have ... National Institute of Dental and Craniofacial Research, part of ... of the genetic roots of cleft lip and cleft ... in Colombia, Nigeria, the Philippines and Pennsylvania. , ... lip or palate that can form when a baby,s ...
(Date:9/30/2014)... Cold Spring Harbor Laboratory (CSHL) will perform research in ... announced in Washington today. The CSHL grants are among ... Health (NIH), totaling $46 million for the 2014-15 fiscal ... Initiative. , The Brain Research through ... in the spring of 2013. It seeks to revolutionize ...
(Date:9/30/2014)... Albany, New York (PRWEB) September 30, 2014 ... Research, a U.S.-based market intelligence agency states that the ... a value of USD 18.5 billion by the end ... was valued at USD 10.3 billion in 2012, will ... develop into a USD 18.5 billion worth market by ...
Breaking Medicine News(10 mins):Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:How to predict who will suffer the most from stress 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 3Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3
... a familiar giant. Smokers around the world find it hard ... buy time by assuming that, cutting// down on the number ... latest research disagrees. ,A study published by ‘Tobacco Control’ ... number of cigarettes you smoke or continue to smoke 15 ...
... statin drug concluded that the drug has the potential to ... with no history of cardiovascular// diseases. But the reduce in ... drug. ,Statins, the best selling and widely ... lowering levels of artery-clogging 'bad' cholesterol, called LDL or low-density ...
... patients have to go through chemotherapy in their battle ... end with the treatment. Many patients complain of// unprecedented ... judgement and comprehension .This seemingly 'fuzzy' experience is also ... has found that these uncomfortable symptoms that trouble a ...
... has forced part of a Wellington based Rita Angus ... down. It has// closed its communal facilities after the ... faeces and vomit of infected people can spread easily ... food, touching surfaces and objects contaminated with the virus. ...
... million grant from the National Institutes of Health, researchers ... whether fat stored around the heart// accelerates the development ... accumulate in the abdomen, as well as around the ... hypothesis that fat around the arteries in the heart ...
... answer to what causes heart attacks is – atherosclerosis - ... on the walls of a coronary artery// until blood flow ... is not always the cause for having a heart attack. ... result in chest pain known as angina and other related ...
Cached Medicine News:Health News:For Smokers Only: is Quitting = Cutting Down?? a 'grave' Issue 2Health News:After Effects Of Chemotherapy Will Wane In Few Years :Says Research 2Health News:Researchers Study Effects Of Fat Around The Heart 2Health News:New Research Project Underway To Study Causes Of Heart Attack 2
The Spex SkinSkan is the only in-vivo, fibre-optic spectrofluorometer designed specifically for skin-fluorescence measurements. It is also ideal for many remote sensing steady-state fluorescence appl...
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
... Quantitation of DNA, RNA, Or Fluorescent Tags. Accurate ... is critical to life science research. The RF-Mini ... measure quantities as small as 1ng/ml of DNA ... of excitation and emission filters, the RF-Mini 150 ...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
Medicine Products: